/

Empresas

AA

No verificado

AAVantgarde

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasLegislación/Derecho/FiscalidadMedicina Salud Bienestar

17 Comunicados de prensa

Ver todos los comunicados de prensa

16/09/2026

Biotecnología

Medicina Salud Bienestar

AAVantgarde to Showcase Clinical Progress in Usher 1B and Stargardt Disease at EURetina 2026

Fuente

Editor

1.00

0

01/09/2026

Biotecnología

AAVantgarde appoints Megan Zoschg Canniere as Chief Regulatory & Quality Officer

Fuente

Editor

1.00

0

23/07/2026

Biotecnología

AAVantgarde Announces Participation of Founder and CSO, Prof. Alberto Auricchio at the 32nd Annual Meeting of the Japanese Society for Gene and Cell Therapy

Fuente

Editor

1.00

0

23/04/2026

Biotecnología

AAVantgarde to Participate in ARVO 2026, with Presentations at Key Pre-events and New Clinical Data from the LUCE Phase 1/2 Study

Fuente

Editor

1.00

0

21/04/2026

Biotecnología

Anuncios breves

AAVantgarde announces completion of recruitment in STELLA natural history study

Fuente

Editor

1.00

0

01/04/2026

Biotecnología

AAVantgarde appoints Philip Lao as Senior Vice President of Business Development

Fuente

Editor

1.00

0

15/01/2026

Biotecnología

AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa

Fuente

Editor

1.00

0

08/01/2026

Biotecnología

AAVantgarde to Present at the 44th Annual J.P. Morgan Healthcare Conference

Fuente

Editor

1.00

0

03/11/2025

Biotecnología

Finanzas

AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome

Fuente

Editor

1.00

0

07/10/2025

Biotecnología

AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0